Abridge, San Francisco, CA-based provider of a generative AI platform for clinical conversations, raised $250M in Series D funding.
The round was co-led by Elad Gil and IVP, with participation from Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures, Redpoint Ventures, Spark Capital, and SV Angel
The company intends to use the funds to further enhance additional development of AI capabilities and commercial growth to support broader applications.
Abridge was founded in 2018 to empower understanding in healthcare. Its AI platform transforms medical conversations into clinically useful and billable documentation at the point of care, reducing administrative burden and clinician burnout while improving patient experience. With the EHR integration, support for 28+ languages, and 50+ specialties, it is used across a wide range of care settings, including outpatient, emergency department, and inpatient.
Supported by Linked Evidence, Abridge provides a solution that maps AI-generated summaries to source data, helping clinicians quickly trust and verify the output.
The Abridge Contextual Reasoning Engine enables:
- Contextual awareness beyond the conversation: integrating data from retrospective patient encounters, health system-specific revenue cycle guidelines, and clinician documentation preferences to create more comprehensive, personalized notes.
- Precise problem detection: intelligently recognizing and grouping medical problems, describing them with language that aligns with appropriate billing codes to simplify downstream revenue cycle workflows.
- Actionable outputs: capturing medical orders and integrating them into the electronic health record, ready for clinician review.
- Auditable notes: tying AI-generated outputs to source information across all input data—powered by Linked Evidence.
FinSMEs
17/02/2025